Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects

Niibe, Yuzuru; Nishimura, Tetsuo; Inoue, Tetsuya; Karasawa, Katsuyuki; Shioyama, Yoshiyuki; Jingu, Keiichi; Shirato, Hiroki

Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects

Niibe, Yuzuru; Nishimura, Tetsuo; Inoue, Tetsuya et al.

BMC cancer, 2016, 16, 659

Permalink : https://hdl.handle.net/2115/75513

このアイテムのアクセス数:579件（2026-10-10 06:07 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
https://doi.org/10.1186/s12885-016-2680-8			25

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/75513
タイトル	Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjects
著者	Niibe, Yuzuru ; Nishimura, Tetsuo ; Inoue, Tetsuya ; Karasawa, Katsuyuki ; Shioyama, Yoshiyuki ; Jingu, Keiichi ; Shirato, Hiroki
e-Rad_Researcher 00372912 著者名 Niibe, Yuzuru
e-Rad_Researcher 30115498 著者名 Nishimura, Tetsuo
e-Rad_Researcher 10431363 著者名 Inoue, Tetsuya
e-Rad_Researcher 80177617 著者名 Karasawa, Katsuyuki
e-Rad_Researcher 10323304 著者名 Shioyama, Yoshiyuki
e-Rad_Researcher 00451592 著者名 Jingu, Keiichi
e-Rad_Researcher 20187537 著者名 Shirato, Hiroki
言語	英語
キーワード	Non-small cell lung cancer (NSCLC)
	Oligo-recurrence
	Oligometastases
	Stereotactic radiosurgery (SRS)
	Stereotactic radiotherapy (SRT)
発行日	2016-08-19
出版者	BioMed Central
収録物名	BMC cancer
巻(号)	16
ページ	659
抄録	Background: To investigate the prognostic value of oligo-recurrence in patients with brain-only oligometastases of non-small cell lung cancer (NSCLC) treated with stereotactic radiosurgery (SRS) or stereotactic radiotherapy (SRT). Methods: Patients treated with SRS or SRT for brain-only NSCLC oligometastases in 6 high-volume institutions in Japan between 1996 and 2008 were reviewed. Eligible patients met 1), 2), and 4) or 1), 3), and 4) of the following: 1) NSCLC with 1 to 4 brain metastases on magnetic resonance imaging (MRI) treated with SRS or SRT; 2) control of the primary lesions (thorax) at the time of SRS or SRT for brain metastases (patients meeting this criterion formed the oligo-recurrence group); 3) with SRS or SRT for brain metastases, concomitant treatment for active primary lesions (thorax) with curative surgery or curative stereotactic body radiotherapy (SBRT), or curative chemoradiotherapy (sync-oligometastases group); and 4) Karnofsky performance status (KPS) ≥70. Results: The median overall survival (OS) of all 61 patients was 26 months (95 % CI: 17.5–34.5 months). The 2-year and 5-year overall survival rates were 60.7 and 15.7 %, respectively. Stratified by oligostatus, the sync-oligometastases group achieved a median OS of 18 months (95 % CI: 14.8–21.1 months) and a 5-year OS of 0 %, while the oligo-recurrence group achieved a median OS of 41 months (95 % CI: 27.8–54.2 months) and a 5-year OS of 18.6 %. On multivariate analysis, oligo-recurrence was the only significant independent factor related to a favorable prognosis (hazard ratio: 0.253 (95 % CI: 0.082–0.043) (p = 0.025). Conclusions: The presence of oligo-recurrence can predict a favorable prognosis of brain-only oligometastases in patients with NSCLC treated with SRS or SRT.
資源タイプ	学術雑誌論文
出版タイプ	Version of Record
権利情報	Creative Commons Attribution 4.0 International
EISSN	1471-2407
NCID	AA12034763
関連情報	PMID 27542716
関連情報 (isIdenticalTo)	出版社版DOI https://doi.org/10.1186/s12885-016-2680-8